These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36367476)

  • 1. pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer.
    Zhu SW; Ye M; Ma X; Wu ZZ; Wan SC; Yang SC; Li H; Xu Z; Sun ZJ
    Acta Biomater; 2022 Dec; 154():497-509. PubMed ID: 36367476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
    Yang Z; Liao J; Carter-Cooper BA; Lapidus RG; Cullen KJ; Dan H
    BMC Cancer; 2019 May; 19(1):485. PubMed ID: 31118072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
    Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
    Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
    Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
    Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-loaded polymeric nanoparticles based on α-tocopheryl succinate for the treatment of head and neck squamous cell carcinoma:
    Riestra-Ayora J; Sánchez-Rodríguez C; Palao-Suay R; Yanes-Díaz J; Martín-Hita A; Aguilar MR; Sanz-Fernández R
    Drug Deliv; 2021 Dec; 28(1):1376-1388. PubMed ID: 34180747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.
    von Mässenhausen A; Sanders C; Brägelmann J; Konantz M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Lengerke C; Perner S
    Int J Cancer; 2016 Nov; 139(10):2359-69. PubMed ID: 27434411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.
    Lehman CE; Spencer A; Hall S; Shaw JJP; Wulfkuhle J; Petricoin EF; Bekiranov S; Jameson MJ; Gioeli D
    Sci Rep; 2021 May; 11(1):10826. PubMed ID: 34031486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer.
    Lo YL; Lin HC; Tseng WH
    Acta Biomater; 2022 Nov; 153():465-480. PubMed ID: 36115656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
    Johnson FM; Saigal B; Talpaz M; Donato NJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming chemotherapy resistance using pH-sensitive hollow MnO
    Zhou ZH; Liang SY; Zhao TC; Chen XZ; Cao XK; Qi M; Huang YY; Ju WT; Yang M; Zhu DW; Pang YC; Zhong LP
    J Nanobiotechnology; 2021 May; 19(1):157. PubMed ID: 34039370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma.
    Rioja-Blanco E; Arroyo-Solera I; Álamo P; Casanova I; Gallardo A; Unzueta U; Serna N; Sánchez-García L; Quer M; Villaverde A; Vázquez E; León X; Alba-Castellón L; Mangues R
    J Exp Clin Cancer Res; 2022 Feb; 41(1):49. PubMed ID: 35120582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
    Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
    J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib.
    Vu AT; Akingunsade L; Hoffer K; Petersen C; Betz CS; Rothkamm K; Rieckmann T; Bussmann L; Kriegs M
    Head Neck; 2023 Jan; 45(1):147-155. PubMed ID: 36285353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microenvironment-Responsive Prodrug-Induced Pyroptosis Boosts Cancer Immunotherapy.
    Xiao Y; Zhang T; Ma X; Yang QC; Yang LL; Yang SC; Liang M; Xu Z; Sun ZJ
    Adv Sci (Weinh); 2021 Dec; 8(24):e2101840. PubMed ID: 34705343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
    Lin YC; Wu MH; Wei TT; Lin YC; Huang WC; Huang LY; Lin YT; Chen CC
    Oncotarget; 2014 Jan; 5(1):298-308. PubMed ID: 24457597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
    Song L; Hao Y; Wang C; Han Y; Zhu Y; Feng L; Miao L; Liu Z
    J Control Release; 2022 Oct; 350():922-932. PubMed ID: 36108810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Li C; Iida M; Dunn EF; Wheeler DL
    Radiother Oncol; 2010 Nov; 97(2):330-7. PubMed ID: 20667610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer.
    Chen F; Tang C; Yang F; Ekpenyong A; Qin R; Xie J; Momen-Heravi F; Saba NF; Teng Y
    Sci Adv; 2024 Feb; 10(8):eadk3663. PubMed ID: 38394204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.